Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
about
Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancerTargeting the hypoxic fraction of tumours using hypoxia-activated prodrugsThe hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancerNovel Phenazine 5,10-Dioxides Release OH in Simulated Hypoxia and Induce Reduction of Tumour Volume In Vivo.Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms.Synthesis, Crystal Structure, and Rotational Energy Profile of 3-Cyclopropyl-1,2,4-benzotriazine 1,4-Di-N-oxide.Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice.Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.The tumor microenvironment in non-small-cell lung cancerCancer therapy with trifunctional antibodies: linking innate and adaptive immunity.Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation.Trial Watch: Anticancer radioimmunotherapy.Tirapazamine has no Effect on Hepatotoxicity of Cisplatin and 5-fluorouracil but Interacts with Doxorubicin Leading to Side Changes in Redox Equilibrium.
P2860
Q24621214-DA7E7FC5-F1ED-4657-B23E-CA35CA010963Q26774750-4E1D2DD4-87D8-412A-9A35-9429426F1B1DQ34005923-EFA88DF5-F952-4112-A92A-99F34CA69135Q34756921-3B2979A4-DD3B-4B7A-9B3A-A9A41476F4FEQ35390655-6545AF12-C60C-4797-A87B-8EA6D0BA3FB2Q35583915-CF585A8B-2624-4B9C-836B-54CB20D593CAQ35707691-C34E5ABB-E9A5-4BD7-AE38-6432358BE471Q37369324-803D4EC0-87D0-42F2-9270-383A867083FEQ37707385-58613376-EF1C-43C4-9444-8CB4E7EB9786Q37777872-E509EB8A-BB19-429F-8348-BE4452FFA38BQ37965555-DC1DD1F6-C6AC-4CD5-9864-83495C09C4C8Q39762897-2B1980EC-0FA0-4095-8F15-698C1E1191DCQ42847992-54AA02F8-5E0F-4BB6-8A5B-6C4C351D99E6Q53144349-615C31D4-C2D5-4F73-9E49-FA298E7C3A11
P2860
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II study of tirapazamine ...... l-cell lung cancer: SWOG 0222.
@en
Phase II study of tirapazamine ...... l-cell lung cancer: SWOG 0222.
@nl
type
label
Phase II study of tirapazamine ...... l-cell lung cancer: SWOG 0222.
@en
Phase II study of tirapazamine ...... l-cell lung cancer: SWOG 0222.
@nl
prefLabel
Phase II study of tirapazamine ...... l-cell lung cancer: SWOG 0222.
@en
Phase II study of tirapazamine ...... l-cell lung cancer: SWOG 0222.
@nl
P2093
P2860
P356
P1476
Phase II study of tirapazamine ...... l-cell lung cancer: SWOG 0222.
@en
P2093
Dennis F Moore
James Moon
John J Crowley
Laurie E Gaspar
Mary Redman
Primo N Lara
Quynh-Thu X Le
Stephen K Williamson
Zelanna Goldberg
P2860
P304
P356
10.1200/JCO.2008.21.3868
P407
P577
2009-04-13T00:00:00Z